Market cap
₹891 Cr
Revenue (TTM)
₹544 Cr
P/E Ratio
10.1
P/B Ratio
2.2
Div. Yield
0.8 %
Quality Score
7/10
Growth Score
5/10
Valuation Score
6/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹88 Cr
-
ROE
23.9 %
-
ROCE
22 %
-
Industry P/E
31.45
-
EV/EBITDA
6.9
-
Debt to Equity
0.3
-
Book Value
₹136.9
-
EPS
₹30.4
-
Face value
5
-
Shares outstanding
29,430,987
10 Years Aggregate
CFO
₹558.80 Cr
EBITDA
₹624.27 Cr
Net Profit
₹283.60 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fermenta Biotech
| -- | -4.5 | -- | -- | -- | -- | -- |
|
BSE Healthcare
| 8.8 | 8.8 | 9.7 | 11.0 | 27.5 | 14.1 | 12.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fermenta Biotech
|
301.5 | 890.7 | 543.7 | 85.0 | 17.3 | 23.7 | 10.1 | 2.2 |
| 3,107.5 | 38,804.4 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 36.7 | 8.6 | |
| 8,587.5 | 21,510.6 | 2,177.5 | 200.9 | 11.3 | 26.5 | 107.1 | 25.9 | |
| 2,028.0 | 15,420.9 | 2,187.2 | 649.7 | 31.5 | 19 | 24 | 4.3 | |
| 1,343.8 | 18,628.3 | 3,129.4 | 647.4 | 26.9 | 18.1 | 30.1 | 4.8 | |
| 2,192.6 | 35,263.5 | 4,147.8 | 709.5 | 22.3 | 18.3 | 49.7 | 8.5 | |
| 4,670.8 | 21,395.8 | 2,519.7 | 722.4 | 33.6 | 18.8 | 29.6 | 5.1 | |
| 5,553.0 | 9,231.7 | 1,348.5 | 293.5 | 28.1 | 50.7 | 31.5 | 13.2 | |
| 490.3 | 9,644.1 | 1,538.1 | 226.2 | 20.4 | 9 | 39.6 | 3.7 | |
| 1,153.2 | 10,628.0 | 4,858.7 | 574.1 | 14.9 | 19.7 | 19.1 | 3.4 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Fermenta Biotech
DIL Limited, together with its subsidiaries, manufactures and sells bulk drugs and enzymes in India, Europe, and internationally. The company operates through Property and Chemicals segments. It is also involved in renting of properties. The company... was formerly known as Duphar-Interfran Ltd. The company was founded in 1951 and is based in Thane, India. DIL Limited is a subsidiary of DVK Investments Private Limited. Read more
-
Incorporated
1951
-
Chairman
--
-
Managing Director
Prashant Nagre
-
Headquarters
Thane, Maharashtra
-
Website
Looking for more details about Fermenta Biotech Ltd.’s IPO? Explore our IPO Details page.
Quarterly Updates
Annual Reports
FAQs for Fermenta Biotech
What is the current share price of Fermenta Biotech Ltd Today?
The share price of Fermenta Biotech Ltd is ₹301.45 (NSE) and ₹302.65 (BSE) as of 22-May-2026 IST. Fermenta Biotech Ltd has given a return of --% in the last 1 years.
What is the current PB & PE ratio of Fermenta Biotech Ltd?
The P/E ratio of Fermenta Biotech Ltd is 10.15 times as on 22-May-2026, a 68 discount to its peers’ median range of 31.45 times.
The P/B ratio of Fermenta Biotech Ltd is 2.21 times as on 22-May-2026, a 52 discount to its peers’ median range of 4.62 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
10.38
|
2.20
|
|
2024
|
0.00
|
1.58
|
|
2023
|
0.00
|
1.02
|
|
2022
|
38.41
|
1.66
|
|
2021
|
15.87
|
2.07
|
What is the 52 Week High and Low of Fermenta Biotech Ltd?
The 52-week high and low of Fermenta Biotech Ltd are Rs 330.00 and Rs 248.85 as of 24-May-2026.
What is the market cap of Fermenta Biotech Ltd?
Fermenta Biotech Ltd has a market capitalisation of ₹ 891 Cr as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Fermenta Biotech Ltd?
Before investing in Fermenta Biotech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.